BeyondSpring to Present at Two Upcoming Scientific Conferences in December
Rhea-AI Summary
BeyondSpring (NASDAQ: BYSI) announced its participation in two significant upcoming events: the 62nd American Society of Hematology (ASH) Annual Meeting (December 5-8, 2020) and the San Antonio Breast Cancer Symposium (SABCS) (December 8-11, 2020). Notably, the company will present findings from the PROTECTIVE-2 Trial, focusing on the Plinabulin and Pegfilgrastim combination's efficacy in preventing chemotherapy-induced neutropenia in breast cancer patients. Presentations will include a poster at ASH on December 5 and three posters at SABCS starting December 9, 2020, featuring research by Dr. Douglas W. Blayney from Stanford University.
Positive
- None.
Negative
- None.
News Market Reaction – BYSI
On the day this news was published, BYSI gained 5.32%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
- BeyondSpring to present at the 62nd American Society of Hematology (ASH) Annual Meeting and at the 2020 San Antonio Breast Cancer Symposium
NEW YORK, Nov. 24, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced a poster presentation about the PROTECTIVE-2 Trial (ClinicalTrials.gov ID: NCT03294577) at the 62nd American Society of Hematology (ASH) Annual Meeting being held virtually December 5-8, 2020. The Company will also present three posters about the PROTECTIVE-1 Trial and PROTECTIVE-2 Trial at the San Antonio Breast Cancer Symposium (SABCS) being held virtually December 8-11, 2020.
Details for the ASH Poster Presentation
| Title: | Protective-2 (BPI-2358-106): A Confirmatory Trial to Demonstrate Superiority of the Plinabulin+Pegfilgrastim (Plin/Peg) Combination Versus Standard of Care Pegfilgrastim for the Prevention of Chemotherapy-Induced Neutropenia (CIN) in Breast Cancer (BC) Patients (pts) | |
| Abstract: | 817 | |
| Session: | 201. Granulocytes, Monocytes, and Macrophages: Poster I Hematology Disease Topics & Pathways: Therapies, Combinations, Clinically relevant | |
| Date/Time: | Saturday, December 5, 2020 from 7:00 a.m.-3:30 p.m. PST | |
| Presenter: | Douglas W. Blayney, M.D. (Stanford University) | |
Details for the SABCS Poster Presentations
| Title: | Plinabulin and Pegfilgrastim (Plin+Peg) versus Peg monotherapy (Peg) after TAC: A comparison of efficacy, safety, relative dose intensity (RDI) and bone pain | |
| Publication #: | PS11-15 | |
| Date/Time: | starting Wednesday, December 9, 2020 at 8:00 a.m. CST (available on-demand) | |
| Presenter: | Douglas W. Blayney, M.D. (Stanford University) | |
| ----------- | ||
| Title: | Protective-2 (bpi-2358-106): a confirmatory trial to demonstrate superiority of the plinabulin+pegfilgrastim (plin/peg) combination versus standard of care pegfilgrastim for the prevention of chemotherapy-induced neutropenia (cin) in breast cancer (bc) patients (pts) | |
{"@context":"https://schema.org","@type":"FAQPage","name":"BeyondSpring to Present at Two Upcoming Scientific Conferences in December FAQs","mainEntity":[{"@type":"Question","name":"What will BeyondSpring present at the 62nd ASH Annual Meeting?","acceptedAnswer":{"@type":"Answer","text":"BeyondSpring will present a poster on the PROTECTIVE-2 Trial, demonstrating the superiority of Plinabulin plus Pegfilgrastim versus standard Pegfilgrastim for preventing chemotherapy-induced neutropenia."}},{"@type":"Question","name":"When is the SABCS presentation by BeyondSpring scheduled?","acceptedAnswer":{"@type":"Answer","text":"The San Antonio Breast Cancer Symposium presentation will begin on December 9, 2020, with three posters related to the PROTECTIVE-1 and PROTECTIVE-2 Trials."}},{"@type":"Question","name":"Who is presenting BeyondSpring's findings at these events?","acceptedAnswer":{"@type":"Answer","text":"Dr. Douglas W. Blayney from Stanford University will present the findings from BeyondSpring's Trials."}},{"@type":"Question","name":"What is the focus of the PROTECTIVE-2 Trial presented by BeyondSpring?","acceptedAnswer":{"@type":"Answer","text":"The PROTECTIVE-2 Trial focuses on the efficacy of the Plinabulin and Pegfilgrastim combination in preventing chemotherapy-induced neutropenia in breast cancer patients."}},{"@type":"Question","name":"What dates are the ASH and SABCS events taking place?","acceptedAnswer":{"@type":"Answer","text":"The ASH Annual Meeting is from December 5-8, 2020, and the SABCS event is from December 8-11, 2020."}}]}
FAQWhat will BeyondSpring present at the 62nd ASH Annual Meeting?
BeyondSpring will present a poster on the PROTECTIVE-2 Trial, demonstrating the superiority of Plinabulin plus Pegfilgrastim versus standard Pegfilgrastim for preventing chemotherapy-induced neutropenia.
When is the SABCS presentation by BeyondSpring scheduled?
The San Antonio Breast Cancer Symposium presentation will begin on December 9, 2020, with three posters related to the PROTECTIVE-1 and PROTECTIVE-2 Trials.
Who is presenting BeyondSpring's findings at these events?
Dr. Douglas W. Blayney from Stanford University will present the findings from BeyondSpring's Trials.
What is the focus of the PROTECTIVE-2 Trial presented by BeyondSpring?
The PROTECTIVE-2 Trial focuses on the efficacy of the Plinabulin and Pegfilgrastim combination in preventing chemotherapy-induced neutropenia in breast cancer patients.
What dates are the ASH and SABCS events taking place?
The ASH Annual Meeting is from December 5-8, 2020, and the SABCS event is from December 8-11, 2020.
Beyondspring Inc
NASDAQ:BYSIBYSI RankingsBYSI Latest NewsBYSI Latest SEC FilingsDec 15, 2025
[8-K] BeyondSpring Inc. Reports Material Event
Nov 21, 2025
[8-K] BeyondSpring Inc. Reports Material Event
BYSI Stock Data |